CING.NASDAQCingulate INC

Form 4: Cingulate Inc. Executive Acquires Stock Options as Part of Compensation Plan

Sentiment:

Insider Transaction Report


Cingulate Inc.'s Executive Vice President and Chief Scientific Officer, Raul R. Silva, acquired 2,000 stock options with exercise prices of $4.30 and $4.07, set to expire in 2035.

Summary

  • Raul R. Silva, Executive Vice President and Chief Scientific Officer of Cingulate Inc., acquired 1,000 stock options with an exercise price of $4.30 per share, exercisable as of March 31, 2025, and expiring on March 31, 2035.
  • Silva also acquired an additional 1,000 stock options with an exercise price of $4.07 per share, exercisable as of June 30, 2025, and expiring on June 30, 2035.
  • Both option grants were made pursuant to the terms of Dr. Silva's Employment Agreement, as amended.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a key executive is a routine compensation event that aligns management's interests with shareholder value, reflecting standard corporate governance practices. It is neither significantly positive nor negative in isolation.

Positives

  • The grant of stock options to a key executive like Raul R. Silva aligns management's financial interests directly with the long-term performance and shareholder value of Cingulate Inc.

Management Comments

  • The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended.

Industry Context

The grant of stock options to key executives is a common practice in the biotechnology and pharmaceutical industries, serving as a standard component of executive compensation packages designed to incentivize long-term performance and align management interests with shareholder returns.

Related Party Transactions

  • The stock options were granted to Raul R. Silva, an executive of Cingulate Inc., pursuant to his employment agreement, representing a transaction between the company and a related party.

Stakeholder Impact

  • Shareholders: The option grants are intended to align the interests of the EVP and CSO with those of the shareholders, potentially leading to improved long-term company performance.
  • Employees: The compensation structure for executives can influence overall company culture and compensation philosophy.

Key Dates

DateDescription
03/31/2025Transaction date and date exercisable for the first grant of 1,000 stock options.
06/30/2025Transaction date and date exercisable for the second grant of 1,000 stock options.
07/01/2025Date the Form 4 was signed and filed.
03/31/2035Expiration date for the first grant of 1,000 stock options.
06/30/2035Expiration date for the second grant of 1,000 stock options.

Keywords

Cingulate Inc., CING, Stock Options, Executive Compensation, Insider Transaction, Form 4, Raul R. Silva, Equity Compensation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.